ROME, ItalyThe combination of paclitaxel (Taxol), fluorouracil (5-FU),
and leucovorin, with G-CSF support, in pretreated patients with advanced
breast cancer had a good toxicity profile and an encouraging response rate
in a study from the Regina Elena Cancer Institute, Rome.
In the poster presentation, Dr. E. Terzoli described 16 heavily pretreated
advanced breast cancer patients who received paclitaxel, 135 to 175 mg/m²on
day 1 and fluorouracil, 350 to 375 mg/m², plus leucovorin, 10 to 100
mg/m², on days 1 to 3. The cycle was repeated every three weeks with
G-CSF added to prevent neutropenia.
The combination therapy was delivered as first-line metastatic treatment
in three patients, second-line in five patients, and third-line or higher
in eight patients. All patients had received previous anthracyclines, and
eight had taken hormones.
Five of 10 evaluable patients had a partial response, and in four of
these patients, the treatment represented third-line chemotherapy. Overall,
the combination was well tolerated.